Table 1 Baseline characteristics of the cohort
Parameter | All (N = 16) | TAVR (N = 9) | SAVR (N = 7) |
|---|---|---|---|
Age (years) | 57 (44; 60) | 56 (44; 59) | 57 (46; 66) |
Sex | |||
male | 11 (69%) | 5 (56%) | 6 (86%) |
female | 5 (31%) | 4 (44%) | 1 (14%) |
Weight (kg) | 69.5 (59.8; 78.1) | 72 (66.3; 78) | 69 (57.5; 82.5) |
Height (cm) | 174 (165; 179) | 168 (163; 179) | 175 (173; 178) |
BMI (kg/m2) | 23.7 (21.7; 27.1) | 23.7 (23.3; 26.5) | 22.5 (20; 29) |
Chronic dialysis prior to procedure | |||
Yes | 6 (38%) | 2 (22%) | 4 (57%) |
No | 10 (62%) | 7 (78%) | 3 (43%) |
Insulin-dependent diabetes mellitus | |||
Yes | 4 (25%) | 3 (33%) | 1 (14%) |
No | 12 (75%) | 6 (67%) | 6 (86%) |
Pre-procedural medication: | |||
ASS | 6 (38%) | 1 (11%) | 5 (71%) |
Clopidogrel | 1 (6%) | 1 (11%) | 0 (0%) |
Vitamin K antagonist | 4 (25%) | 4 (44%) | 0 (0%) |
direct oral anticoagulation | 1 (6%) | 1 (11%) | 0 (0%) |
Statin | 11 (69%) | 6 (67%) | 5 (71%) |
Coronary angiogram prior to procedure | |||
No stenosis in need of an intervention | 14 (88%) | 7 (78%) | 6 (86%) |
Implantation of drug-eluting stent | 1 (6%) | 1 (1%) | 0 (0%) |
Simultaneous intervention planned with TAVR/SAVR | 0 (0%) | 0 (0%) | 0 (0%) |
Secondary coronary intervention planned after TAVR/SAVR | 1 (6%) | 0 (0%) | 1 (14%) |
